Graf Global Receives NYSE Warning for Late 10-K Filing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy GRAF?
Graf Global received a notice on April 16 from the NYSE American stating that the company is not in compliance with the NYSE American Company Guide because it has not timely filed its Annual Report on Form 10-K as of and for the year ended December 31, 2025 with the SEC. The Notice has no immediate effect on the listing or trading of the Company's securities. However, if the company fails to timely regain compliance with the Rule, the company's securities will be subject to delisting. The company intends to file the Annual Report as soon as practicable to regain compliance with the rule.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAF
About GRAF
Graf Global Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The Company neither engaged in any operations nor generated any revenues.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Sales Forecast Downgrade: Travere Therapeutics expects U.S. net product sales of $410 million for 2025 and $127 million for Q4 2026, indicating pressure on future revenue growth that could undermine investor confidence.
- Clinical Trial Restart: The company plans to restart the Phase 3 HARMONY study in Q1 2026, aiming to advance product development, but this may not alleviate the short-term stock price decline.
- Severe Market Reaction: Shares of Travere Therapeutics plummeted 28.2% to $24.50 in pre-market trading, reflecting a pessimistic outlook from the market that may lead investors to reassess their strategies.
- Other Stock Volatility: Lulu’s Fashion Lounge Holdings surged 79% on acquisition news but fell 10.4% in pre-market trading, highlighting the high volatility in market sentiment that could impact the overall investment landscape.
See More
- Significant Stock Surge: Heritage Global Inc's shares rose 19.1% to $1.62 in pre-market trading, reflecting strong market confidence in the company's growth potential following the acquisition announcement.
- Acquisition Details: The company's subsidiary, Heritage DebtX, acquired substantially all assets of The Debt Exchange, which not only strengthens its asset base but also enhances its competitive position in the debt trading market.
- Strong Market Reaction: The acquisition news generated significant investor interest, with Heritage Global's stock performing notably well in pre-market trading, indicating market approval of its strategic direction.
- Future Growth Potential: This acquisition positions Heritage Global to capture a larger market share in debt management and trading, potentially leading to long-term revenue growth and business expansion opportunities.
See More







